Ron Menezes , , , President and Chief Executive Officer

View bioHide bio

Ron Menezes joined Sientra in November 2020 as President and Chief Executive Officer. Ron’s most recent experience includes serving as President and General Manager for Almirall U.S. – Dermatology, where he led exceptional growth and profitability improvements, returning the U.S. division to profitability. Ron was also part of the team that successfully acquired Allergan’s dermatology assets in 2018. In 2019, he led the launch of a new molecule for the treatment of acne that far exceeded revenue goals by strategically focusing on improving patients’ access to the product. Prior to Almirall, Ron was the Vice President of Sales and Marketing for Dermatology at Allergan, leading the team to more than 20% yearly growth between 2013 and 2015. The growth was driven by increased direct-to-consumer advertising and expanding the promotion of a 20-year-old topical product for acne. As a head of sales for SkinMedica, Latisse and Medical Dermatology, Ron was part of the commercial team that successfully launched a new direct-to-physician sunscreen product. While at SkinMedica, he focused on expanding national accounts that were responsible for driving most of the growth in 2015. Ron has also held key leadership responsibilities at Abbott, Astellas Pharma – U.S., Pfizer and Eli Lilly. Ron holds a B.S. in International Business from Brigham Young University and earned a certificate in Health Care Management from the University of Utah.

Oliver Bennett , , , Chief Legal, Compliance, & Corporate Development Officer

View bioHide bio

Oliver Bennett joined Sientra in 2015, first as outside counsel and then as general counsel to the company, prior to becoming General Counsel and Vice President for Compliance and Legal in 2018. Oliver brings with him almost two decades of experience in counseling medical device and life science companies in complex and high stakes legal issues. Prior to joining Sientra, he practiced law at a number of premier firms where he was at the cutting edge of legal practice representing clients in ground-breaking cases that have helped shape US law. Most recently, Oliver was a partner at Kirkland & Ellis LLP. Before that, he was Of Counsel at Kaye Scholer LLP (now Arnold White Kaye Scholer LLP), and an associate at Latham & Watkins, LLP and Clifford Chance US LLP. Oliver received a Master in Laws degree from Harvard Law School where he was also a Fulbright Scholar, and Bachelor of Laws and Bachelor of Arts degrees from Griffith University in Brisbane, Australia.

Denise Dajles , , Dr. , , Chief Technical Officer

View bioHide bio

Dr. Denise Dajles joined Sientra in June 2021 as Vice President of Research and Development. Most recently, Denise served as Senior Director of Research, Development and Innovation leading the science and technology department at Establishment Labs. In this role, she was responsible for the successful execution of more than ten new product and technology projects, which includes several regulatory approvals for commercialization in the United States, Europe, Latin America and Asia Pacific, as well as for leading extensive scientific research. Previously, Denise was an advisor, investigator, and Interim Director in the Biomedical Engineering Lab at the University of Costa Rica School of Engineering. Denise holds both a Bachelor of Science and Master of Science in Biomedical Engineering from Washington University, St. Louis and a Doctorate in Engineering from The George Washington University, Washington, DC. She has co-authored several peer reviewed publications and is a named inventor on a number of technologies.

Matt Hostetler , , , Chief People Officer

View bioHide bio

Matt Hostetlerjoined Sientra in April 2022. He brings over 20 years of global Human Resources leadership in biotech and consumer products. Matt is known for designing and implementing sustainable HR strategies in complex environments that positively impact business performance. Prior to joining Sientra, Matt was the head of HR for Kite Pharma, A Gilead Company. Earlier in his career, Matt held multiple leadership roles at Amgen and Honeywell. He earned both his Master of Labor and Human Resources and his Bachelor of Science in Business from The Ohio State University.

Andy Schmidt , , , Chief Financial Officer

View bioHide bio

Andy Schmidt joined Sientra in July 2021. Andy brings to Sientra more than 20 years of financial leadership experience and has successfully directed the financial, M & A and capital market strategies of numerous publicly held companies. Most recently, he served as the CFO of Guardion Health Sciences, a Nasdaq-listed company focused on clinical nutrition, diagnostics, and medical devices. Previously, he served as the CFO of Iteris, Inc., a publicly traded global technology company. With a focus on internal and external strategic development and execution, Andy accelerated growth and achieved record stock performance. Prior, he was the CFO of publicly traded Smith Micro Software, Inc. and Genius Products, Inc. Earlier, he served in financial leadership roles with Peregrine Systems and Mad Catz Interactive. Andy received a Master of Science in Accountancy from San Diego State University and a Bachelor of Business Administration in Finance from the University of Texas, Austin, TX.

Mark Saxton , , , Senior Vice President Sales

View bioHide bio

Mark Saxton joined Sientra in May 2023 and is an accomplished commercial leader with over 30 years of industry experience. Mark joined us after four years as the Vice President of Sales for NeuroPace, a medical device company offering innovative treatment for people suffering from drug-resistant epilepsy, leading them through Covid to a successful IPO. From 2017 to 2019, through their acquisition by Smith & Nephew, Mark served as Vice President of Sales and Marketing at Ceterix Orthopedics, Inc., a medical device company with a novel meniscus repair solution. Prior to that, Mark served as Vice President of Product Solutions at Integer Holding Corp., a medical device manufacturing and outsourcing company, where he was responsible for sales and marketing for finished devices and new product development in the Cardio and Vascular division. Mark also headed the sales and customer service organizations at Neuronetics, inc. a manufacturer of a disruptive neuromodulation device for Major Depressive disease and VNUS Medical Technologies, a market maker for endovenous ablation for the treatment of venous reflux disease, through its acquisition by Covidien. Mark earned a B.B.A. in Marketing and Business Administration from Western Michigan University.

Adelle Walker , , , Senior Vice President Corporate Strategy and Marketing

View bioHide bio

Adelle Walker joined Sientra in July 2023 as Senior Vice President, Corporate Strategy and Marketing. Adelle has a deep background in aesthetics, diagnostics, capital equipment, medical device, injectables and medically reimbursed specialty markets, responsible for leading the strategic and commercial execution plans with both new-to-market launches and on market high profile brands. Most recently, Adelle stood up a consumer products division at DermTech responsible for leading the development of D2C skin cancer DNA test division, where she launched a premarket disease awareness campaign delivering more than 12X the market impact growth. Prior to DermTech, Adelle lead a consulting business focused on market analysis and global product launches to physicians and consumers in both medical and aesthetic markets. Adelle also held the Chief Marketing Officer role at SENTE where she launched the physician dispensed skincare brand via e-commerce, returning the line to growth with an omni channel approach. At Candela, Adelle lead the build of the Global Marketing team in the US leading the growth of a large portfolio of laser systems which lead to the successful sale to Private Equity. Adelle also held key marketing leadership roles at Allergan over 13 years. She was the Head of Marketing for the Medical Dermatology Division and doubled the sales over three years through focusing on D2C and HCP pull through strategies. She also had other key Marketing Leadership roles at Allergan including heading up the aesthetic fillers group of Juvederm and leading a team of retail practice managers at SkinMedica.

Nasdaq: SIEN

Stock Quote: NASD

$0.17 -0.04
Volume 3,435,111
Previous Close 0.21
Intraday High 0.20
Intraday Low 0.16
Pricing delayed 20 minutes
Price Change % Change -18.69% 52 Week High 4.94 52 Week Low 0.16 Today's Open 0.19 Feb 21, 2024 04:00 PM

Investor Contact

Sientra Investor Relations
ir@sientra.com